Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998110 | 0.87 | P4HTM (0.48) | P4HTMBTK | |
| SCHEMBL5997052 | 0.84 | CSF1R (0.64) | TYK2MAPTCSF1R | |
| SCHEMBL5997760 | 0.83 | TYK2 (0.51) | TYK2BTKBLKMAPTCSF1R | |
| SCHEMBL15100315 | 0.81 | TYK2 (0.70) | TYK2MAPTCSF1R | |
| SCHEMBL5996482 | 0.81 | SRC (0.51) | TYK2BTKBLKMAPTLCK | |
| SCHEMBL5996063 | 0.77 | PDGFRB (0.56) | TYK2BTKBLKLCK | |
| SCHEMBL2324574 | 0.76 | RORC (0.57) | P4HTMRORCMAPT | |
| SCHEMBL15561708 | 0.76 | — | — | |
| SCHEMBL5281904 | 0.75 | LCK (0.58) | TYK2P4HTMRORCLCK | |
| SCHEMBL2495621 | 0.75 | BTK (0.75) | BTKBLKLCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | TYK2 5/4885P4HTM 3856/4885BTK 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.